Experiences with

Ombitasvir / Paritaprevir / Ritonavir

As an update to several earlier posts about the use of Pemivibart for COVID. It seems the FDA is about to limit its use to only as a pre-exposure prophylaxis agent for COVID-19 in immunocompromised patients. Here is the MedPage article dated August 27, 2024 in full: * * * [i]MedPage Today - Infectious

...but is it ineffective in younger age groups? The issue is, the study in question https://www.nejm.org/doi/full/10.1056/NEJMoa2204919?query=TOC&cid=NEJM%20eToc,%20August%2025,%202022%20DM1379474_NEJM_Non_Subscriber&bid=1131122421 looked at "Nirmatrelvir Use and Severe Covid-19 Outcomes during the

Dear All, After six emails I got a response from my MP ... nothing spectacular but nonetheless helpful. However, the apparent preference to depend on treatment rather than prevention is worrying. "Thank you for your correspondence of 25 April on behalf of your constituent, about COVID-19 treatments.

Hi . I have GPA and I am identified as being clinically extremely vulnerable due to the fact that I take immune suppressants (Azathioprine and Prednisolone). I recently became infected with Covid 19 and became very ill. Because I became ill on the weekend I so had to book a courier to pick up my PCR

Hi everyone, I have updated our website article about the COVID-19 treatments for those who are at higher risk for severe illness from COVID-19 infection. https://www.lupusuk.org.uk/covid-19-treatments/ There have been a couple of important changes: 1.Lateral flow tests are now accepted as confirmation

This post, prepared in collaboration with        AussieNeil , draws together some earlier posts relating to SARS-CoV-2 infection and CLL. COVID-19 RISK FOR CLL PATIENTS Due to their impaired humoral and cellular immune function, CLL patients are at particular risk for infection, including

This is from the FDA fact sheet- PAXLOVID is contraindicated with drugs that are potent CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance. PAXLOVID cannot be started immediately

On 22 December the U.S. Food and Drug Administration issued an emergency use authorisation (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults. Pfizer has also announced an agreement

Thousands of vulnerable patients could be taking ground-breaking COVID-19 antivirals this winter after the government announced deals to secure 2 new treatments. These treatments should speed up recovery time for COVID-19 patients and the most vulnerable will be eligible first, including the elderly

ModraDoc006/Ritonavir Offers Promising Therapeutic Option for mCRPC, Convenient Approach Amid COVID-19 Pandemic February 8, 2021 Dr. Ulka N. Vaishampayan ModraDoc006, a novel oral docetaxel formulation, has advantages as a convenient, oral, and better-tolerated potential therapeutic option for patients

A triple-antiviral therapy regimen of interferon-beta1, lopinavir/ritonavir, and ribavirin shortened median time to COVID-19 viral negativity (mild to moderate cohorts) in a small, randomized trial (n=84) done by the University of Hong Kong (China). The median hospital stay was 9 days for patients treated

Sorry that the link was blocked in the EU. It is open source, so here is the text, along with the citation of the source. Just to put in a plug for Healthgrades - it is a terrific on-line resource where patients rate physicians and the ratings are summarized and posted. Very helpful when looking for

Coronavirus drugs: Where we are and what we know by Amina Khan Medicines designed to treat COVID-19 won't be on pharmacy shelves for months or even years, but thousands of patients are in hospitals and health clinics now. So doctors are looking to drugs that are already approved for treating other diseases

The world’s largest randomised clinical trial of potential coronavirus treatments is well underway in the UK as part of the race to find a treatment. A number of promising treatments are being tested and, if the science supports it, will be given to NHS patients as quickly as possible. Definitive results

A European clinical trial involving some 3,200 people has been launched to test four possible experimental treatments against the coronavirus, AFP reports. The four treatments to be studied are remdesivir, lopinavir and ritonavir in combination, the latter being administered with or without interferon

Potential Pipeline Medications May Help Patients with Novel Coronavirus https://www.pharmacytimes.com/news/potential-pipeline-medications-for-the-coronavirus Below is a bit of this article. It talks specifically about Remdesivir, Hydroxychloroquine, Umifenovir, Baloxavir, Favipiravir, Lopinavir and Ritonavir

Hi, this post is about my father, he is 62 years. He was diagnosed with hepatitis and ultrasound confirmed nodules, cirrhosis and ascites. He never took alcohol all his life. When he was admitted in hospital, he was given human albumin (via IV), diuretics and Ritonavir (antiretroviral I guess). Recent

Clarithromycin, darunavir, grapefruit juice, itraconazole, ketoconazole, lopinavir, mifepristone, nefazodone, nelfinavir, ombitasvir, paritaprevir, ritonavir, posaconazole, saquinavir, telaprevir, telithromycin, verapamil, voriconazole.

HCV genotype 3: 12 weeks of sofosbuvir, ribavirin, and pegylated interferon HCV genotype 4: 12 weeks of ledipasvir and sofosbuvir OR paritaprevir, ritonavir, ombitasvir, and ribavirin, OR 24 weeks of sofosbuvir and ribavirin. HCV genotype 5 or 6: sofosbuvir and ledipasvir.

http://www.prnewswire.com/news-releases/abbvie-demonstrates-commitment-to-hepatitis-c-patients-with-new-data-on-viekira-pak-ombitasvir-paritaprevir-ritonavir-tablets-dasabuvir-tablets-and-ongoing-clinical-development-program-at-the-liver-meeting-2015-300152779.html?$G1Ref